Analysts forecast that Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) will report earnings of ($0.34) per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Opiant Pharmaceuticals’ earnings, with estimates ranging from ($0.41) to ($0.26). Opiant Pharmaceuticals posted earnings of ($0.05) per share in the same quarter last year, which would suggest a negative year over year growth rate of 580%. The business is scheduled to issue its next earnings report on Thursday, August 5th.
On average, analysts expect that Opiant Pharmaceuticals will report full-year earnings of ($1.93) per share for the current financial year, with EPS estimates ranging from ($2.60) to ($0.91). For the next fiscal year, analysts forecast that the business will report earnings of ($4.52) per share, with EPS estimates ranging from ($9.00) to ($1.11). Zacks’ EPS calculations are a mean average based on a survey of research firms that follow Opiant Pharmaceuticals.
Opiant Pharmaceuticals (NASDAQ:OPNT) last announced its earnings results on Tuesday, May 11th. The technology company reported ($0.66) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.71) by $0.05. The firm had revenue of $6.39 million for the quarter, compared to the consensus estimate of $5.29 million. Opiant Pharmaceuticals had a negative return on equity of 8.67% and a negative net margin of 9.52%.
Shares of OPNT opened at $13.24 on Friday. The firm has a market cap of $57.34 million, a P/E ratio of -18.39 and a beta of 0.75. Opiant Pharmaceuticals has a 12 month low of $6.79 and a 12 month high of $14.98. The stock’s 50-day moving average is $12.01. The company has a debt-to-equity ratio of 0.55, a current ratio of 9.12 and a quick ratio of 9.12.
In other news, Director Gabrielle Alison Silver sold 13,006 shares of Opiant Pharmaceuticals stock in a transaction dated Wednesday, March 17th. The stock was sold at an average price of $11.31, for a total value of $147,097.86. Company insiders own 28.02% of the company’s stock.
Institutional investors have recently modified their holdings of the stock. Apis Capital Advisors LLC bought a new stake in Opiant Pharmaceuticals in the 4th quarter valued at about $514,000. Renaissance Technologies LLC increased its position in Opiant Pharmaceuticals by 9.7% in the 4th quarter. Renaissance Technologies LLC now owns 236,815 shares of the technology company’s stock valued at $1,902,000 after buying an additional 20,900 shares in the last quarter. Wells Fargo & Company MN increased its position in Opiant Pharmaceuticals by 21.9% in the 4th quarter. Wells Fargo & Company MN now owns 252,205 shares of the technology company’s stock valued at $2,025,000 after buying an additional 45,255 shares in the last quarter. Morgan Stanley increased its position in Opiant Pharmaceuticals by 11.8% in the 1st quarter. Morgan Stanley now owns 9,476 shares of the technology company’s stock valued at $101,000 after buying an additional 1,000 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its position in Opiant Pharmaceuticals by 11.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 21,831 shares of the technology company’s stock valued at $232,000 after buying an additional 2,253 shares in the last quarter. 20.96% of the stock is owned by institutional investors and hedge funds.
About Opiant Pharmaceuticals
Opiant Pharmaceuticals, Inc, a specialty pharmaceutical company, develops medicines for addictions and drug overdose. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes medicines for the treatment for opioid overdose reversal; alcohol use disorders; acute cannabinoid overdose; and opioid use disorders.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Opiant Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.